Evolus, Inc. (EOLS) Q4 Earnings and Revenues Lag Estimates

Company Performance - Evolus, Inc. reported quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.06 per share, compared to a loss of $0.14 per share a year ago, representing an earnings surprise of -83.33% [1] - The company posted revenues of $78.95 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 0.08%, but showing an increase from year-ago revenues of $61 million [2] - Over the last four quarters, Evolus has not surpassed consensus EPS estimates, although it has topped consensus revenue estimates two times [2] Stock Performance - Evolus shares have increased by approximately 29.9% since the beginning of the year, while the S&P 500 has declined by -0.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $71.81 million, and for the current fiscal year, it is $0.21 on revenues of $351.93 million [7] Industry Outlook - The Medical - Products industry, to which Evolus belongs, is currently in the top 36% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry performance can significantly impact stock performance [5][8]